Saturday 17 October 2026
Export NBTX’s income statement to Excel — free account
Nanobiotix S.A. - Sponsored ADR
NBTX Healthcare Biotechnology
21.30
0.93
−4.18%
Follow NBTX
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
1.31 | 0.95 | 0.49 | 0.89 | |
Current Ratio |
1.44 | 1.09 | 0.63 | 1.04 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | (0.36) | (0.20) | (0.52) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | — | 0.00% | — | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (38.42) | (19.94) | (22.07) | |
Working Capital |
43.66 | 5.93 | (26.28) | 2.74 | |
Capital Expenditures |
— | (0.61) | (0.18) | (0.91) | |
Net Current Asset Value |
(44.45) | (101.25) | (84.27) | (77.54) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.80 | 1.70 | 1.64 | 1.66 | |
Average Payables |
15.40 | 15.03 | 15.72 | 15.91 | |
Average Assets |
121.28 | 89.14 | 47.67 | 67.96 | |
Average Common Equity |
(31.13) | (48.79) | (68.46) | (49.80) |
Columns are period end dates · fundamentals updated 28 Sep 2026